Disease · MONDO_0004114

urinary bladder small cell neuroendocrine carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. urinary bladder small cell neuroendocrine carcinoma. Diseases, record MONDO_0004114. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004114

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: urinary bladder small cell neuroendocrine carcinoma; Open Targets
Open Targets ID: MONDO_0004114; Open Targets
Other names: SCCB, bladder small cell neuroendocrine cancer, bladder small cell neuroendocrine carcinoma, poorly differentiated neuroendocrine carcinoma of the bladder, small cell bladder cancer, small cell bladder carcinoma, small cell carcinoma of the urinary bladder, small cell carcinoma of urinary bladder, small cell neuroendocrine carcinoma of the urinary bladder, small cell neuroendocrine carcinoma of urinary bladder, urinary bladder small cell carcinoma; Open Targets
Disease Ontology: DOID:7132; Disease Ontology
NCI Thesaurus: C9461; NCI Thesaurus
Orphanet: ORPHA:284400; Orphanet
Highest stage of its drugs: Phase 2, for 4 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets22

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 inhibitor	Phase 1	https://conductscience.org/library/genes/5133	Drugs and targets
CD274	Programmed cell death 1 ligand 1	1	Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 1	https://conductscience.org/library/genes/1493	Drugs and targets
KDR	Vascular endothelial growth factor receptor 2	1	Vascular endothelial growth factor receptor 2 inhibitor	Phase 1	https://conductscience.org/library/genes/3791	Drugs and targets
MET	Hepatocyte growth factor receptor	1	Hepatocyte growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/4233	Drugs and targets
TOP2A	DNA topoisomerase II	1	DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
TOP2B	DNA topoisomerase II	1	DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7155	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/84790	Drugs and targets

1 to 10 of 22

See all 22 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03582475	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate	Phase 1	15	2025-06-10	Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Prostate Small Cell Carcinoma, Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8, Stage III Prostate Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Ureter Small Cell Carcinoma, Urothelial Carcinoma	CARBOPLATIN, CISPLATIN, DOCETAXEL, ETOPOSIDE, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02496208	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	Phase 1	152		Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Sarcomatoid Urothelial Carcinoma, Kidney Medullary Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Penile Carcinoma, Penile Squamous Cell Carcinoma, Renal Cell Carcinoma, Renal Pelvis Urothelial Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma	CABOZANTINIB, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT05312671	Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer	Phase 2	63		Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder	ATEZOLIZUMAB, CARBOPLATIN, CISPLATIN, ETOPOSIDE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer vs Cohort 2: Small Cell or Neuroendocrine Prostate Cancer: deaths from any cause	3 of 7	3 of 8	15	NCT03582475	Trial comparisons
Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer vs Cohort 2: Small Cell or Neuroendocrine Prostate Cancer: serious adverse events	7 of 7	7 of 8	15	NCT03582475	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39536751	DERIVED	1	PubMed
38954785	DERIVED	1	PubMed
35031545	DERIVED	1	PubMed
32915679	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004114

GET https://conductscience.org/api/diseases/v1/MONDO_0004114/targets?page=2

API reference For AI assistants